Eagle Rock Investment Company LLC Buys 1,048 Shares of Cencora, Inc. (NYSE:COR)

Eagle Rock Investment Company LLC boosted its position in shares of Cencora, Inc. (NYSE:COR) by 2.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 39,040 shares of the company’s stock after purchasing an additional 1,048 shares during the period. Cencora comprises 1.5% of Eagle Rock Investment Company LLC’s holdings, making the stock its 17th largest position. Eagle Rock Investment Company LLC’s holdings in Cencora were worth $8,772,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. State Street Corp lifted its position in shares of Cencora by 3.8% in the third quarter. State Street Corp now owns 8,045,896 shares of the company’s stock worth $1,810,970,000 after purchasing an additional 291,867 shares in the last quarter. Wellington Management Group LLP increased its stake in Cencora by 7.0% in the 3rd quarter. Wellington Management Group LLP now owns 5,193,386 shares of the company’s stock valued at $1,168,927,000 after buying an additional 338,452 shares during the last quarter. Geode Capital Management LLC lifted its position in Cencora by 4.7% during the 3rd quarter. Geode Capital Management LLC now owns 4,195,851 shares of the company’s stock worth $941,183,000 after buying an additional 189,054 shares in the last quarter. Pacer Advisors Inc. boosted its stake in shares of Cencora by 6,855.3% during the 3rd quarter. Pacer Advisors Inc. now owns 2,065,374 shares of the company’s stock worth $464,874,000 after buying an additional 2,035,679 shares during the last quarter. Finally, Legal & General Group Plc grew its holdings in shares of Cencora by 3.7% in the 2nd quarter. Legal & General Group Plc now owns 1,875,445 shares of the company’s stock valued at $422,538,000 after acquiring an additional 67,287 shares in the last quarter. Institutional investors and hedge funds own 97.52% of the company’s stock.

Insider Buying and Selling at Cencora

In other Cencora news, Chairman Steven H. Collis sold 21,509 shares of the company’s stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $242.16, for a total value of $5,208,619.44. Following the transaction, the chairman now directly owns 306,752 shares of the company’s stock, valued at $74,283,064.32. This represents a 6.55 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, EVP Silvana Battaglia sold 1,678 shares of Cencora stock in a transaction on Friday, December 20th. The stock was sold at an average price of $228.72, for a total value of $383,792.16. Following the sale, the executive vice president now directly owns 20,329 shares of the company’s stock, valued at $4,649,648.88. This represents a 7.62 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 94,696 shares of company stock valued at $22,862,734 in the last three months. 15.80% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

COR has been the topic of several analyst reports. Leerink Partners dropped their target price on Cencora from $277.00 to $275.00 and set an “outperform” rating on the stock in a report on Monday, October 7th. Barclays upped their price objective on Cencora from $263.00 to $290.00 and gave the stock an “overweight” rating in a research note on Thursday, November 7th. Wells Fargo & Company decreased their target price on shares of Cencora from $249.00 to $237.00 and set an “equal weight” rating for the company in a research note on Friday, December 13th. StockNews.com lowered shares of Cencora from a “strong-buy” rating to a “buy” rating in a research report on Friday, September 20th. Finally, Evercore ISI lifted their price objective on shares of Cencora from $250.00 to $285.00 and gave the company an “outperform” rating in a research report on Thursday, November 7th. Two equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $275.60.

Cencora Price Performance

NYSE:COR opened at $240.51 on Friday. The company has a market cap of $46.49 billion, a P/E ratio of 32.03, a P/E/G ratio of 1.48 and a beta of 0.49. The firm’s fifty day moving average price is $237.65 and its two-hundred day moving average price is $233.72. Cencora, Inc. has a one year low of $214.77 and a one year high of $253.27. The company has a debt-to-equity ratio of 4.84, a current ratio of 0.88 and a quick ratio of 0.53.

Cencora Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, November 29th. Investors of record on Friday, November 15th were paid a $0.55 dividend. The ex-dividend date of this dividend was Friday, November 15th. This represents a $2.20 dividend on an annualized basis and a yield of 0.91%. This is a positive change from Cencora’s previous quarterly dividend of $0.51. Cencora’s dividend payout ratio is 29.29%.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.